Browse by author
Lookup NU author(s): Dr Zoe Bell, Dr Corey ChanORCiD, Rachel Howarth, Andrea Atkinson, Zakareya Gamie, Dr Daniel Frankel, Dr Oana BretcanuORCiD, Dr Kenneth RankinORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Copyright © 2026 The Authors. Objectives: Chondrosarcoma is the most common type of primary bone sarcoma in adults with a high risk of local recurrence and metastasis. Chondrosarcomas are largely resistant to chemotherapy and radiotherapy, meaning that surgery is the mainstay of treatment for most patients. Therefore, new therapeutic targets are required. Cluster of differentiation 44 (CD44) is a transmembrane protein that has roles in cell proliferation, adhesion and migration and is shown to be overexpressed in several cancer types. Consequently, this work was undertaken to understand whether CD44 could be a potential therapeutic target in chondrosarcoma. Methods: In this study, tissue sections from chondrosarcoma patients were evaluated for CD44 expression using immunohistochemical analysis. The relationship between CD44 expression in the patient tissue and overall and event-free survival was investigated. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing was used to generate a CD44 knockout chondrosarcoma cell line which was used for a spheroid invasion assay to understand the role of CD44 in chondrosarcoma cell invasion. Results: Cox multivariate analysis of CD44 expression in chondrosarcoma patient tissue revealed that high CD44 expression was linked to decreased overall (p < 0.01) and event-free survival (p < 0.01). The observed invasion of CD44 knockout cells in the spheroid assay was less than that of the wild type cells (p < 0.001). Conclusions: The increased expression of CD44 in intermediate and high grade chondrosarcomas, as well as reduced invasion of CD44 knockout cells suggests that CD44 plays an important role in chondrosarcoma progression and metastasis. These findings support further investigation of CD44 as an imaging and/or therapeutic target for the management of chondrosarcoma.
Author(s): Bell Z, Chan CD, Howarth R, Atkinson A, Gamie Z, Frankel D, Bretcanu O, Rankin KS
Publication type: Article
Publication status: Published
Journal: Oncology Research
Year: 2026
Volume: 34
Issue: 7
Online publication date: 16/06/2026
Acceptance date: 01/04/2026
Date deposited: 29/06/2026
ISSN (print): 0965-0407
ISSN (electronic): 1555-3906
Publisher: Tech Science Press
URL: https://doi.org/10.32604/or.2026.075617
DOI: 10.32604/or.2026.075617
Data Access Statement: The data that supports the findings of this study are available from the corresponding author, [Kenneth S. Rankin], upon reasonable request.
Altmetrics provided by Altmetric
